The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
Survival of patients with advanced solid tumors who receive treatment in community based oncology group practices is comparable to randomized controlled trials (RCT).
 
Rudolf Weide
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Geothy Chakupurakal
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Stefan Feiten
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Vera Friesenhahn
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Kristina Kleboth
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Hubert Koeppler
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Julia Lutschkin
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Jörg Thomalla
No Relationships to Disclose
 
Christoph van Roye
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)
 
Oswald Burkhard
No Relationships to Disclose
 
Marcel Reiser
No Relationships to Disclose
 
Peter Ehscheidt
No Relationships to Disclose
 
Jochen Heymanns
Research Funding - Biotest (Inst); Celgene (Inst); CSL Behring (Inst); Eisai (Inst); Hexal (Inst); Medac (Inst); Megapharm (Inst); Novartis (Inst); Octapharm (Inst)